VELPHORO 500 MG — DIN 02471574
IRON (SUCROFERRIC OXYHYDROXIDE) : 500 MG · VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD · TABLET (CHEWABLE) · wholesale supply in Canada
Health Canada status: MARKETED
What is VELPHORO?
VELPHORO 500 MG contains IRON (SUCROFERRIC OXYHYDROXIDE) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02471574, held by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD, supplied as TABLET (CHEWABLE) for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Nov-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VELPHORO used for?
Velphoro (sucroferric oxyhydroxide) is indicated for the control of serum phosphorus levels in adult patients with end-stage renal disease (ESRD) on dialysis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET (CHEWABLE) |
| Route | ORAL |
| Pack configuration (monograph) | Available in a high density polyethylene (HDPE) bottle containing 90 chewable tablets. |
| Storage | Store at room temperature (15 to 30°C). Store in the original package and keep the bottle tightly closed in order to protect from moisture. Use within 90 days of opening bottle. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Sucroferric Oxyhydroxide |
|---|---|
| ATC code | V03AE05 |
| AHFS class | 40:18.19 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02471574 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2471574 |
| Brand name | VELPHORO |
| Generic / active ingredient | IRON (SUCROFERRIC OXYHYDROXIDE) : 500 MG |
| Market authorization holder | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD |
| Health Canada schedule | Prescription |
| ATC code | V03AE05 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V03AE |
| Current status | MARKETED |
| Status date | 20-Nov-2019 |
| Original market date | 2019-11-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC V03AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Polystyrene Sulphonate | JAMP CALCIUM POLYSTYRENE SULFONATE · JAMP SODIUM POLYSTYRENE SULFONATE · K-EXIT POUDRE · KAYEXALATE · +8 more | 16 | 7 | Yes |
| Lanthanum Carbonate | FOSRENOL · NAT-LANTHANUM | 8 | 4 | Yes |
| Sevelamer | ACCEL-SEVELAMER · INTELLI-SEVELAMER · RENAGEL · RENVELA | 8 | 3 | Yes |
| Patiromer Calcium | VELTASSA | 3 | 2 | Yes |
| Sodium Zirconium Cyclosilicate | LOKELMA | 2 | 2 | Yes |
| Sucroferric Oxyhydroxide | VELPHORO | 1 | 1 | Yes |
| Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia | PHOSLO TABLETS | 1 | 0 | Not in Canada |
| Calcium Acetate | CALCIUM ACETATE TAB 667MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V03AC | Deferasirox · Deferiprone · Deferoxamine | 57 | 44 |
| V03AN | Carbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more | 112 | 43 |
| V03AB | Amyl Nitrite · Andexanet Alfa · Antidotes · Digitalis Antitoxin · Dimercaprol · +16 more | 87 | 31 |
| V03AF | Amifostine · Calcium Folinate · Dexrazoxane · Mesna · Palifermin · +1 more | 34 | 16 |
| V03AH | Diazoxide | 2 | 1 |
| V03AX | Cobicistat · Difelikefalin · Other Therapeutic Products | 8 | 1 |
| V03AZ | Ethanol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.